Cenexi Q2 dip due to summer shutdown
Management acknowledged that Q2 FY26 will see lower EBITDA at Cenexi due to a one-month thermal shutdown, potentially delaying the turnaround trajectory.
GLAND / Q1-FY26 / risks
Keep the risk register visible.
Gland Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
U.S. tariff uncertainty on pharmaceuticals
An analyst raised concerns about potential U.S. tariffs under the Trump administration. Management noted no tariffs on pharma yet but acknowledged uncertainty and said they would pass on costs to partners.
Enoxaparin revenue volatility
U.S. revenue was flat due to timing of Enoxaparin supplies, a large product. Management expects annual volumes to be intact but quarterly volatility may persist.
GLP-1 capacity utilization ramp-up slower than expected
Management indicated that the new 100 million cartridge line will not see significant utilization until FY29-30, as most markets open later. Near-term revenue contribution may be limited.